rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Cumberland Pharmaceuticals Inc.

CPIX · Nasdaq

Health CareBiotechnologyLeading

CPIX stood above a rising 150-day average in 29 of the last 52 weekly readings, including each of the last 25 weeks. It is 21.7% above that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Leading
Weeks in an uptrend
25 in a row
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
31 (+5)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 29 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$13KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders31+5 on the quarter
New · exited8 · 3
Reported value$16.0M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Ikarian Capital, LLCreduced · filed 14 Aug 2026503,153$3.3M-50,000−9.0%
RENAISSANCE TECHNOLOGIES LLCadded · filed 13 Aug 2026478,263$3.1M+7,567+1.6%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026379,478$2.5M+17,719+4.9%
DIMENSIONAL FUND ADVISORS LPreduced · filed 11 Aug 2026233,305$1.5M-43,054−15.6%
BOOTHBAY FUND MANAGEMENT, LLCreduced · filed 14 Aug 2026112,544$729K-15,150−11.9%
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 2026108,413$703K-5,880−5.1%
PERCEPTIVE ADVISORS LLCreduced · filed 14 Aug 202696,982$628K-99,996−50.8%
CITADEL ADVISORS LLCadded · filed 14 Aug 202673,391$476K+56,748+341.0%
BlackRock, Inc.added · filed 7 Aug 202663,547$412K+6,656+11.7%
Bank of New York Mellon Corpunchanged · filed 6 Aug 202658,458$379K00.0%
31 Mar 2023 – 30 Jun 2026
182430Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

A. J. Kazimi Company insiderChairman and CEO · last 18 Mar 2026471 · 1
Caroline Young Company insiderDirector · last 18 Mar 2026583 · 0
Chris T. Bitterman Company insiderVice Pres Sales & Marketing · last 18 Mar 20260 · 0
James Jones Company insiderDirector · last 18 Mar 2026472 · 0
James L. Herman Company insiderVP and Chief Compliance Office · last 18 Mar 20260 · 0
John M. Hamm Company insiderVP Chief Financial Officer · last 18 Mar 20261 · 0
Joseph C. Galante Company insiderDirector · last 18 Mar 2026455 · 0
Kenneth Krogulski Company insiderDirector · last 18 Mar 2026593 · 0
Martin S. Brown Jr. Company insiderDirector · last 18 Mar 20260 · 0
Todd M. Anthony Company insiderVice Pres Organizational Dev · last 18 Mar 20260 · 0
Joey A. Jacobs Company insiderDirector · last 14 Jan 202338 · 0
Leo Pavliv Company insiderSVP and Chief Development Off. · last 31 May 20221 · 1

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202551.3%
Operating profit marginFY 2025 · to 31 Dec 2025-20.4%
Free cash flow marginFY 2025 · to 31 Dec 202535.3%
Return on capital employedFY 2025 · to 31 Dec 2025-7.0%
Interest coverFY 2025 · to 31 Dec 2025-5.63×
Research spendFY 2025 · to 31 Dec 202540.7%
Revenue growthFY 2025 · to 31 Dec 202565.0%
Earnings per share growthFY 2025 · to 30 Jun 2025-163%
Share count trendFY 2025 · to 4 Mar 20260.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$11.4M
Free cash flowFY 2025 · to 31 Dec 2025$4.8M

Analyst forecasts

No analyst forecasts yet.